More on Novartis (NVS) Q3: Net profit of $2.48B vs $2.49B. Earnings hurt by patent expirations, with Diovan (blood pressure) sales -32% to $969M after losing protection in September. Sandoz generic division revs -6%. New drugs helping to offset the patent cliff, and account for 29% of sales vs 25% a year ago. Consumer Health division sales -16% to $938M, due to manufacturing problems at Nebraska plant.